To acclimate to hypoxia, tumor cells develop defective apoptosis through HIF1-mediated variations in pro- and anti-apoptotic members of the Bcl-2 protein family, which represents a pivotal explanation for drug resistance [27]. This evidence concerns the gene HIF1A and neoplasm.